Navigation Links
Iomai Trial Shows 100 Percent Immune Response in Elderly Subjects Vaccinated With Novel Travelers' Diarrhea Patch Vaccine
Date:8/19/2007

s necessary to conduct additional clinical trials or to market any product for travelers' diarrhea; that estimates of market size overstate the number of travelers who would use such a product, if it were approved; that competitors may develop products that are safer, more effective, or more convenient to use; and the risks identified under the heading "Factors That May Impact Future Results" in Management's Discussion and Analysis of Financial Condition and Results of Operations in Iomai's Quarterly Report on Form 10-Q for the three months ended March 31, 2007, and filed with the Securities and Exchange Commission. While Iomai believes that this product candidate is amenable to self-administration, in the Phase 2 study described in this press release, medical professionals administered the vaccine. Whether any approved product would be self-administered would depend on many factors, including the outcome of any studies the Company conducts evaluating self-administration and the views of regulatory agencies. Iomai cautions investors and others not to place undue reliance on the forward-looking statements contained in this press release. Iomai's business is subject to many risks. For a discussion of such risks, you are encouraged to read the documents the Company files with the U.S. Securities and Exchange Commission, available at http://www.sec.gov.

The statements in this press release speak only as of the date of this document, and Iomai undertakes no obligation to update or revise the statements.


'/>"/>
SOURCE Iomai Corporation

Copyright©2007 PR Newswire.

Page: 1 2 3 4

Related medicine technology :

1. Iomai to Announce Results From Phase 1 Influenza Trial and Host Webcast Tomorrow
2. Iomai Dose-Ranging Trial Demonstrates Needle-Free Patch Vaccine for Travelers Diarrhea Stimulates Immune Response Even at Low Doses
3. Antisoma Announces Further Data From ASA404 Ovarian Cancer Trial
4. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
5. Halozyme Therapeutics Enhanze Technology Large Protein Molecule Therapeutic Clinical Trial Results Presented at the 34th Annual Meeting of the Controlled Release Society
6. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
7. Gene Therapy Eradicates Pancreatic Cancer in Preclinical Trial Targeting Systems Success in Mouse Model Reported in Cancer Cell
8. AM-Pharma Announces Positive Results of Phase IIa Clinical Trial with Alkaline Phosphatase For Ulcerative Colitis
9. Phase III Trial Results Show Superiority of Rivaroxaban over Enoxaparin for the Prevention of Venous Thromboembolism in Patients Undergoing Knee Replacement Surgery
10. Phase III Trial Results Show Superiority of Rivaroxaban over Enoxaparin for the Prevention of Venous Thromboembolism in Patients Undergoing Knee Replacement Surgery
11. TransPharma Medical Announces Positive Results of Phase I Clinical Trials for Transdermal Delivery of hPTH (1-34) for Osteoporosis Treatment
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/23/2015)... and BOSTON , January 23, 2015 ... discovery and development company, is delighted to announce that the ... awarded to Miles Congreve (Vice President of Chemistry), ... Malcolm Weir (Chief Executive Officer and co-founder) for ...
(Date:1/22/2015)... Jan. 22, 2015  BiOptix is pleased to announce the ... President of Chemistry and Biochemistry. Scott joins the company after ... and Amgen throughout the course of his nearly 20 ... "Scott is a nationally recognized thought leader in the ...
(Date:1/22/2015)... 2015 /PRNewswire/ - Pivotal Therapeutics Inc. (OTCQX:PVTTF; CSE:PVO), ("Pivotal" or the ... therapies for cardiovascular disease and overall health is pleased to ... 2014 and its outlook for 2015 from the CEO, Mr. ... We would like to take this opportunity to share ...
Breaking Medicine Technology:Heptares Scientists to Receive the Malcolm Campbell Memorial Prize for 2015 in Recognition of Their Outstanding Contribution to GPCR Drug Discovery 2Heptares Scientists to Receive the Malcolm Campbell Memorial Prize for 2015 in Recognition of Their Outstanding Contribution to GPCR Drug Discovery 3Heptares Scientists to Receive the Malcolm Campbell Memorial Prize for 2015 in Recognition of Their Outstanding Contribution to GPCR Drug Discovery 4BiOptix Expands Leadership Team with the Appointment of Dr. Scott Klakamp as Vice President of Chemistry and Biochemistry 2Pivotal Therapeutics: Year in Review and CEO Update 2Pivotal Therapeutics: Year in Review and CEO Update 3Pivotal Therapeutics: Year in Review and CEO Update 4Pivotal Therapeutics: Year in Review and CEO Update 5Pivotal Therapeutics: Year in Review and CEO Update 6Pivotal Therapeutics: Year in Review and CEO Update 7
... Sunpeaks Ventures, Inc. (OTCBB: SNPK) (PINKSHEETS: SNPK) ... announce that it has completed the acquisition of ... of hard-to-find and specialty drugs.  In addition to ... markets Clotamin ® , a specialized over-the-counter multivitamin ...
... YORK, Feb. 29, 2012 Keryx Biopharmaceuticals, Inc. (NASDAQ: ... the acquisition, development and commercialization of medically important pharmaceutical ... and renal disease (the "Company"), today announced its results ... 2011. At December 31, 2011, the Company ...
Cached Medicine Technology:Sunpeaks Ventures Completes Acquisition of Healthcare Distribution Specialists LLC 2Keryx Biopharmaceuticals, Inc. Announces Fourth Quarter and Year-End 2011 Financial Results 2Keryx Biopharmaceuticals, Inc. Announces Fourth Quarter and Year-End 2011 Financial Results 3Keryx Biopharmaceuticals, Inc. Announces Fourth Quarter and Year-End 2011 Financial Results 4Keryx Biopharmaceuticals, Inc. Announces Fourth Quarter and Year-End 2011 Financial Results 5
(Date:1/22/2015)... For over 20 years, Dr. David Cruz of ... area has treated just about every type of injury that can ... for those same twenty-plus years, the team at Doctors on ... the best possible doctor. With the combined breadth of ...
(Date:1/22/2015)... January 22, 2015 Yesterday, Senator ... (D-Concord) and Kristin Olsen (R-Modesto) were honored by ... in advancing biotechnology, biomedical science, medical device and ... each received the “2014 Life Sciences Champion” award ...
(Date:1/22/2015)... Payday lending practices in four southern states ... distress to the states that permit them, according to ... on Race and Wealth. , While they generate hundreds ... at the same time substantially depress economic activity, according ...
(Date:1/22/2015)... has released a new blog post presenting a list of vehicles ... , Some types of vehicles cannot be covered under an ... post to see if their vehicle qualifies for auto insurance coverage. ... the cars that cannot be covered by a plan. Clients have ...
(Date:12/26/2014)... The US represents the largest market for CRC across ... estimates that sales of branded therapies were $2.23 billion. The ... incidence of the disease, high drug treatment rate, and higher ... sales of CRC therapies over the forecast period will be ...
Breaking Medicine News(10 mins):Health News:Industry Leading Chiropractor in Oceanside Joins the Doctors on Liens Network 2Health News:California Biomedical Community Honors Senator Holly Mitchell, Assemblymembers Susan Bonilla & Kristin Olsen 2Health News:California Biomedical Community Honors Senator Holly Mitchell, Assemblymembers Susan Bonilla & Kristin Olsen 3Health News:Howard University Spotlights the Economic Impact of Payday Lending in Southern States 2Health News:Some Vehicles Cannot Be Covered By An Auto Insurance Policy! 2Health News:US Colorectal Cancer Drug Market Analysis and Forecast to 2023 Report Available at ReportsnReports.com 2Health News:US Colorectal Cancer Drug Market Analysis and Forecast to 2023 Report Available at ReportsnReports.com 3Health News:US Colorectal Cancer Drug Market Analysis and Forecast to 2023 Report Available at ReportsnReports.com 4
... have engineered a way to deliver health-promoting nutrients using ... breakthrough could lead to low fat or non-fat foods ... and could be used to enrich foods with other ... ,The team, led by Dr. Yoav D. Livney of ...
... future of cancer detection and treatment may be in gold ... be seen by the naked eye.// The potential of gold ... in a stable, nontoxic form that can be injected into ... found that a plant extract can be used to overcome ...
... leading pharmaceutical companies, issued a press release that stated ... cancer. ,A Phase III clinical trial ... (mitoxantrone) plus prednisone. The study included a little over ... disease after hormonal therapy., ,The results of the ...
... Delhi: The incidence of malaria, one of the most common ... cases in 2005 to 1.2 million cases in 2006, the ... the social sectors, the Economic Survey said malaria deaths came ... this period. ,According to it, in some parts ...
... pounds should add daily walks and limit TV time and ... // ,“The childbearing years are a time of particular ... Oken, M.D. “Modifiable behaviors in that early postpartum period — ... a woman’s risk of retaining weight.” ,Oken and ...
... could have better success rates following surgery, thanks to ... ,The study was published in the February, 2007 issue ... journal of the American Academy of Otolaryngology-Head and Neck ... Otolaryngology, the study measured success rates of patching eardrum ...
Cached Medicine News:Health News:Natural Milk Protein Could Lead to Super Nutritious Foods 2Health News:Common Ingredient in Big Macs and Sodas Can Stabilize Gold Nanoparticles for Medical Use 2Health News:Common Ingredient in Big Macs and Sodas Can Stabilize Gold Nanoparticles for Medical Use 3Health News:Incidence of Malaria Has Come Down, Says Economic Survey 2Health News:Simple Solutions to Postpartum Weight Retention 2Health News:Inner-ear Volume Study Leads to Higher Surgery Success Rates 2
The Micro-Temp® II safely and consistently delivers a therapeutic level of localized heat using a pump, connecting hose and localized temperature therapy pad....
Flat Wire Stone Basket...
Stainless Steel Paired Helical Basket...
4 hour identification of over 70 medically important, oxidase-negative, gram-negative bacilli, including E. coli, based on enzyme technology....
Medicine Products: